Screener
Neurocrine Biosciences NBIX EPS (Basic)
EPS (Basic) at other companies
Other financials
Where this comes from
Reported directly by Neurocrine Biosciences in its filing.
Tagged under the XBRL concept us-gaap:EarningsPerShareBasic.
The source filing: Neurocrine Biosciences’s 10-Q, filed May 5, 2026.
- Filed
- May 5, 2026, 4:02 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0000914475-26-000026
| (in millions, except per share data) | Three Months Ended March 31, 2026 | 2025 |
|---|---|---|
| Unrealized (loss) gain on available-for-sale debt securities, net of tax | (12.7) | 1.7 |
| Comprehensive income | $185.2 | $11.1 |
| Earnings per share: | ||
| Basic | $1.97 | $0.08 |
| Diluted | $1.91 | $0.08 |
| Weighted-average shares outstanding: | ||
| Basic | 100.5 | 99.7 |
| Diluted | 103.4 | 102.5 |
Item 1. Financial Statements
FAQ
- What is Neurocrine Biosciences's EPS (basic)?
- Neurocrine Biosciences (NBIX) reported EPS (basic) of $1.97 in Q1 2026.
- How has Neurocrine Biosciences's EPS (basic) changed year-over-year?
- Neurocrine Biosciences's EPS (basic) increased by 2362.5% year-over-year, from $0.08 to $1.97.
- What is the long-term trend for Neurocrine Biosciences's EPS (basic)?
- Over 4 years (2021 to 2025), Neurocrine Biosciences's EPS (basic) has grown at a 47.1% compound annual growth rate (CAGR), from $1.03 to $4.82.
- What does EPS (basic) mean?
- Net income available to common shareholders divided by the weighted-average number of common shares outstanding during the period. Does not account for dilutive securities.
Ask your AI about Neurocrine Biosciences's eps (basic).
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude